logo
1,400 different bug species found in the guts of Asian hornets

1,400 different bug species found in the guts of Asian hornets

Yahoo04-03-2025

One of the world's largest hornet species appears to have quite a diverse palate. When studying the Asian hornets' (Vespa velutina) gut contents, a team of researchers from the University of Exeter in the United Kingdom, they found evidence of 1,400 different species–including some crucial pollinators. The team saw a wide range of insects such as bees, wasps, beetles, flies, butterflies, moths, and even some arachnids. The findings are detailed in a study published March 4 in the journal Science of The Total Environment.
Also known as yellow-legged-hornets, Asian hornets are a social species of predatory wasp. They are about one inch long and can build nests that can contain up to 6,000 workers. They are native to southeastern Asia and considered an invasive species in Europe and North America. They are particularly threatening to honey bees and other native insects that pollinate important crops. The lack of pollinators can threaten food supplies and the ecosystem as a whole.
Asian hornets are not to be confused with the headline grabbing 'murder hornets' (Vespa mandarinia). They are a different species and were successfully eradicated in the United States last year after first being spotted in 2019.
In the new study, the team looked at Asian hornet samples from France, Spain, and the island of Jersey throughout the hornet's active season. The European honey bee was the most common species found in the hornets' guts, and appeared in all of the sample nests and the larvae from those nests. However, their diet appears to be much more broad than initially expected.
'Asian hornets are known to prey on honey bees, but until now the full range of their diet hasn't been tested,' study co-author and University of Exeter molecular ecologist Siffreya Pedersen said in a statement. 'The diet varied strongly over the seasons and between regions, showing that they are highly flexible predators. 'Most insect populations are in decline due to factors such as habitat destruction and chemical pollution. The expanding area inhabited by Asian hornets poses an extra threat.'
CREDIT: Chris Isaacs.
The team used a method called deep sequencing–which sequences a region of the genome multiple times–to identify the prey species in the guts of more than 1,500 Asian hornet larvae. The larvae typically eat food that is provided by adult hornets.
Of the top 50 invertebrate prey species that the team identified, 43 are known to visit flowers. Europe's top three main crop pollinators–the European honey bee, the buff-tailed bumblebee and the red-tailed bumblebee–were also represented in the samples.
[ Related: How a single honey bee colony led to a species invasion. ]
'Insects play vital roles in enabling ecosystems to function–including pollination, decomposition and pest control,' Pedersen said.
According to the team, this provides additional evidence of the threat that Asian hornets pose as they spread. Gardeners and the general public are encouraged to get to know what these hornets look like and report their nests to local authorities.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's...
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's...

Business Insider

time4 hours ago

  • Business Insider

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's...

Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio. The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains. Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China. Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4 + T cell (CD4 + CER-T cell) with a chimeric antigen receptor CD8 + T cell (CD8 + CAR-T cell) or T cell receptor CD8 + T cell (CD8 + TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States. With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally. Chris Ehrlich, CERo Therapeutics CEO, commented, 'We continue to aggressively expand our intellectual property portfolio, as it ensures CERo's success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design . We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.' About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Want to live a long and happy life? Try trusting friends, strangers, and government, new study says
Want to live a long and happy life? Try trusting friends, strangers, and government, new study says

Yahoo

time17 hours ago

  • Yahoo

Want to live a long and happy life? Try trusting friends, strangers, and government, new study says

Trust in your neighbours, institutions, and society writ large may be a key ingredient to a long and happy life, new research suggests. A study in the journal Psychological Bulletin found that people who are generally more trusting tend to report greater well-being, which measures people's mental health and how content they are with their lives – and is in turn tied to longevity and health. 'Our findings show that trust plays a key role in how happy and satisfied people feel, across all ages, especially so for children, adolescents, and older adults,' Catrin Finkenauer, one of the study's authors and a professor at Utrecht University in the Netherlands, said in a statement. Related Indonesians are flourishing. People in the UK, Germany, and Spain? Not so much, global survey finds For the new study, Finkenauer's team looked at three types of trust: interpersonal trust between people who know each other, trust in institutions like the government and banks, and social trust, or the belief that most people are 'honest, reliable, and benevolent'. They found that people who were more trusting – regardless of the type of trust – tended to report greater well-being. However, the link was stronger among children and teenagers than among adults up through middle age. Trust and well-being also appear to reinforce each other over time, according to the study, a meta-analysis that compiled data from more than 2.5 million people worldwide. Related This small island in Denmark lets stressed students unplug from distractions and study in nature 'Whether it's trust in others, in society, or in institutions, all types matter for well-being,' Finkenauer said. It's not clear whether well-being directly causes health outcomes, but it has been linked to longer lifespans – four to 10 extra years, one analysis from the UK's Ministry of Health found – as well as better mental health and a lower risk of death from heart disease and cancer. Notably, not everyone appears to benefit from trust's boost to well-being. Last year, another study in 38 European countries found that racial and ethnic minorities report lower levels of trust, which can make them more unhappy and dissatisfied with life. Related Where in Europe do teenagers have the best and worst mental health? But that same report found that building trust among minorities helps to boost their well-being, leading researchers to conclude that promoting trust can 'narrow the well-being gap' among people of different backgrounds. 'Trust can't be forced – it has to be earned,' Finkenauer said, adding that families, schools, and governments all bear responsibility for creating supportive, trusting environments. 'When we build trust, we also support mental health and stronger communities,' she said.

Sailing-Racing sailors to double as ocean scientists in European waters
Sailing-Racing sailors to double as ocean scientists in European waters

Yahoo

timea day ago

  • Yahoo

Sailing-Racing sailors to double as ocean scientists in European waters

(Reuters) -Every yacht in this summer's Ocean Race Europe will double as a floating laboratory, gathering vital ocean data as crews battle their way between seven iconic European ports, organisers say. The fleet will gather measurements on water temperature, salinity, oxygen, CO2 levels, microplastics and environmental DNA during the offshore competition from August 10 to September 20. Some teams will deploy drifter buoys designed to transmit meteorological information for years afterward. "We know conditions in our ocean are changing rapidly but scientists need more data to better understand what is happening, the pace of change and how this impacts ocean health," said Lucy Hunt, Ocean Impact Director of The Ocean Race and a marine biologist. "Due to the vastness of the ocean, reliable data is very sparse, and there are many areas that are undersampled." The race begins in Kiel, Germany and visits Portsmouth, Porto, Cartagena, Nice, Genova, and Montenegro's Boka Bay. Organisers report that the 2023 around-the-world race generated more than 4 million data points for researchers. "By putting different configurations of The Ocean Race Science Instruments on different race boats we can broaden the scope of the data we collect," said Stefan Raimund, Scientific Advisor to The Ocean Race. The Ocean Race Europe is a multi-stage offshore sailing competition organised by the same group behind the round-the-world Ocean Race. It features top-tier IMOCA 60 and VO65 yachts crewed by mixed-gender teams. The IMOCA 60 and VO65 are elite ocean racing yachts at the heart of major offshore events. The 60-foot IMOCA is a foiling, carbon-fibre monohull designed for solo or short-handed races, while the 65-foot VO65 is a one-design yacht used in fully crewed races like The Ocean Race.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store